MDL | - |
---|---|
Molecular Weight | 546.66 |
Molecular Formula | C28H26N4O4S2 |
SMILES | COC(C=C1)=CC=C1C2=CSC(NC([C@@H](NS(C3=CC=C(C)C=C3)(=O)=O)CC4=CNC5=C4C=CC=C5)=O)=N2 |
IC50: 0.92 μM (AIMP2-DX2), IC50: >100 μM (AIMP2) [1]
BC-DXI-843 (0.0316-31.6 μM; 72 hours) suppresses cancer cell proliferation in a DX2-dependent manner. The EC 50 in A549 cells is 1.20 μM, which is similar to the IC 50 for inhibition of DX2. However, no inhibition of WI-26 cells is observed, suggesting that BC-DXI-843 specifically reduces the viability of cancer cells [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay [1]
Cell Line: | A549 cancer cells and WI-26 normal cells |
Concentration: | 0.0316, 0.1, 0.316, 1, 3.16, 10, 31.6 μM |
Incubation Time: | 72 hours |
Result: | The EC 50 in A549 cells was 1.20 μM. No inhibition of WI-26 cells was observed. |
BC-DXI-843 (50 mg/kg; intraperitoneally administered; every other day for 15 days) demonstrates in vivo efficacy in a tumor xenograft mouse model (H460 cells) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | 7-week-old female BALB/cSLC-nu/nu mice bearing H460 cells xenograft [1] |
Dosage: | 50 mg/kg |
Administration: | Intraperitoneally administered; every other day for 15 days |
Result: | The embedded tumor volume gradually declined after BC-DXI-843administration, but no changes in body weight were observed. The weight of the excised tumors after sacrifice had decreased in mice. |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
DMSO : 250 mg/mL ( 457.32 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 1.8293 mL | 9.1465 mL | 18.2929 mL |
5 mM | 0.3659 mL | 1.8293 mL | 3.6586 mL |
10 mM | 0.1829 mL | 0.9146 mL | 1.8293 mL |